Algert Global LLC Cuts Position in Insmed, Inc. $INSM

Key Points

• Algert Global LLC has reduced its stake in Insmed, Inc. by 41.4%, holding 44,424 shares after selling 31,330 shares in Q1, valued at approximately $3.39 million.
• Insiders at Insmed have sold a total of 497,829 shares worth about $47.8 million in the last 90 days, indicating a notable decrease in their positions.
• Analysts have expressed positive sentiment towards Insmed, with fifteen analysts rating the stock as a "buy" and an increasing price target of $129.57 on average.

Algert Global LLC trimmed its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 41.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,424 shares of the biopharmaceutical company's stock after selling 31,330 shares during the quarter. Algert Global LLC's holdings in Insmed were worth $3,389,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in INSM. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Insmed during the 1st quarter valued at about $975,000. OneDigital Investment Advisors LLC raised its position in shares of Insmed by 47.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after buying an additional 1,673 shares in the last quarter. Sowell Financial Services LLC purchased a new stake in shares of Insmed during the 1st quarter valued at about $255,000. GAMMA Investing LLC raised its position in shares of Insmed by 62.0% during the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 386 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Insmed by 16.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 541 shares in the last quarter.

Insider Buying and Selling at Insmed

In other news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the transaction, the director owned 274,516 shares of the company's stock, valued at approximately $35,549,822. This represents a 3.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 129,805 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at $23,483,630.36. The trade was a 35.69% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 539,694 shares of company stock worth $53,144,604. Insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on INSM shares. Truist Financial upped their target price on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. HC Wainwright raised their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Bank of America raised their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a report on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $132.57.

Insmed Trading Down 0.5%

Shares of INSM traded down $0.72 during trading hours on Friday, reaching $131.88. 2,098,255 shares of the company traded hands, compared to its average volume of 3,215,877. The firm has a market cap of $27.88 billion, a price-to-earnings ratio of -23.10 and a beta of 0.95. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $133.56. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The stock's fifty day moving average price is $107.48 and its 200 day moving average price is $85.66.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.